Mod GRF 1-29 vs Thymosin Alpha-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | Thymosin Alpha-1 |
|---|---|---|
| Dose Range | 100 mcg–200 mcg | 1.6 mg–3.2 mg |
| Frequency | 3x daily | Less than daily |
| Cycle Length | 8–12 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. |
| Best For |
What They Have in Common
Mod GRF 1-29, Thymosin Alpha-1 are both commonly used for:
Key Differences
Unique to Mod GRF 1-29:
Which Has Stronger Evidence?
- Recovery & Healing: Thymosin Alpha-1 has stronger research support.
| Goal | Mod GRF 1-29 | Thymosin Alpha-1 |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
Thymosin Alpha-1
- Aging and Thymosin Alpha-1.
International journal of molecular sciences, 2025
- Phenotypic drug discovery: a case for thymosin alpha-1.
Frontiers in medicine, 2024
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Inflammopharmacology, 2023
Ready to Learn More?
Looking for trusted sources?